Coronavirus protein redesigned in laboratory, which can enable rapid, stable vaccine production: study

Coronavirus protein redesigned in laboratory, which can enable rapid, stable vaccine production: study

Let’s Start this Interesting Article Shared on

HOUSTON: Scientists have redesigned an important protein from the novel coronavirus that it uses to enter and infect human cells, an innovation that led to much faster and more stable production of vaccines against covid-19 Can.
According to the researchers, most of the candidates for the Kovid-19 vaccine, including those at the University of Texas at Austin in the US, train the human immune system to recognize a key protein on a novel surface called the coronovirus SARS-COV-2, called Spike. goes. S) Protein to fight infection.
In the current study published in the journal Science, scientists have designed a new version of this protein that can be produced 10 times more in cells than many synthetic K proteins already in many Kovid-19 vaccines. is used to.
“Depending on the type of vaccine, this improved version of the protein can reduce the size of each dose or accelerate vaccine production,” study senior author Jason McClellan of the University of Texas at Austin.
“Either way, it could mean that more patients can get vaccines faster,” McLennan said.
The new protein, dubbed Hexapro, is more stable than the team’s older version of the S protein, which according to scientists should make it easier to store and transport.
He added that the new S protein also maintains its shape under heat stress, during storage at room temperature, and through many freeze-thwes – properties that are desirable in a robust vaccine.
In the study, the researchers first identified 100 different modifications of the S protein, which they believed could be a more stable and more highly expressed variant.
They then created 100 different versions of the protein by inserting a genetic blueprint for each variant into a separate culture of human cells.
Of the 100 versions, the scientists stated that 26 were more stable or had higher production in cells, of which they took four beneficial modifications, plus two from their original stable S proteins, and combined them to form hexopro.
The study stated that when they inserted a genetic blueprint for this variant of the S protein into a human cell culture, the cells produced 10 times more protein than their original protein.
According to the study, HexaPro can also be used in Kovid-19 antibody tests where it will act as a test to identify the presence of antibodies in a patient’s blood, indicating that a person has previously been infected with the virus. Has become infected.
Scientists said their earlier S protein variant is the basis for vaccine candidates currently in human clinical trials, including mRNA-1273 developed by the American biotechnology company Modern.
They stated that such vaccine candidates use modified versions of viral genetic material to make coronavirus proteins in human cells to trigger an immune response.
Among these mRNA vaccine candidates, researchers stated that improved S protein may enable the development of vaccines that require very small doses to elicit similar immune responses in people.
From a production standpoint, he stated that “new innovation could mean accelerating access to a lifetime vaccine.”
“High-yield production of a stable prefusion spike protein will accelerate the development of vaccines and serological diagnostics for SARS-COV-2,” the scientists wrote in the study.


Leave a Reply

Your email address will not be published. Required fields are marked *